Prothena Co. PLC (NASDAQ:PRTA) Director Dennis J. Selkoe sold 3,500 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $64.17, for a total value of $224,595.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Prothena Co. PLC (NASDAQ:PRTA) traded down 0.05% during mid-day trading on Wednesday, reaching $63.73. The company’s stock had a trading volume of 174,576 shares. The company’s market capitalization is $2.44 billion. Prothena Co. PLC has a 1-year low of $40.58 and a 1-year high of $70.00. The firm’s 50 day moving average price is $61.21 and its 200-day moving average price is $57.11.

Prothena Co. PLC (NASDAQ:PRTA) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.89) by $0.43. The company had revenue of $26.81 million for the quarter, compared to analyst estimates of $16.08 million. Prothena Co. PLC had a negative net margin of 66.02% and a negative return on equity of 14.44%. Prothena Co. PLC’s revenue for the quarter was up 7951.1% on a year-over-year basis. During the same quarter last year, the business earned ($1.18) EPS. On average, analysts predict that Prothena Co. PLC will post ($4.41) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/04/prothena-co-plc-prta-director-dennis-j-selkoe-sells-3500-shares.html.

PRTA has been the topic of a number of recent analyst reports. ValuEngine upgraded Prothena Co. PLC from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Zacks Investment Research upgraded Prothena Co. PLC from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a report on Friday, August 11th. BidaskClub upgraded Prothena Co. PLC from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 19th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $70.00 price objective on shares of Prothena Co. PLC in a report on Thursday, July 6th. Finally, Royal Bank Of Canada reiterated a “buy” rating on shares of Prothena Co. PLC in a report on Friday, September 29th. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $78.58.

Several institutional investors and hedge funds have recently made changes to their positions in PRTA. Bank of Montreal Can boosted its holdings in shares of Prothena Co. PLC by 6.7% in the 2nd quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 117 shares during the last quarter. Quantbot Technologies LP boosted its holdings in shares of Prothena Co. PLC by 672.7% in the 2nd quarter. Quantbot Technologies LP now owns 1,870 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 1,628 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Prothena Co. PLC by 187.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,375 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 1,549 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new position in shares of Prothena Co. PLC in the 1st quarter valued at $167,000. Finally, Sei Investments Co. acquired a new position in shares of Prothena Co. PLC in the 2nd quarter valued at $176,000.

About Prothena Co. PLC

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Insider Buying and Selling by Quarter for Prothena Co. PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Co. PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Co. PLC and related companies with MarketBeat.com's FREE daily email newsletter.